RBC Capital Downgrades Immunogen Inc. (IMGN) to Sector Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall St futures mixed ahead of CPI, bank earnings; US-Iran tensions in focus
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
Immunogen's (IMGN) Price Target Reduced to $5 at Morgan Stanley
May 2, 2016 9:49 AM EDTMorgan Stanley maintained an Underweight rating on Immunogen Inc. (NASDAQ: IMGN) and lowered its price target to $5.00 (from $9.00).
For an analyst ratings summary and ratings history on Immunogen Inc. click here. For more ratings news on Immunogen Inc. click here.
Shares of Immunogen Inc. closed at $6.85 yesterday.
... MoreUPDATE: RBC Capital Cuts Immunogen Inc. (IMGN) to 'Sector Perform' on Concerns About Lead Asset
April 29, 2016 2:28 PM EDT(Updated - April 29, 2016 2:44 PM EDT)
RBC Capital downgraded Immunogen Inc. (NASDAQ: IMGN) from Outperform to Sector Perform with a price target of $7.00 (from $18.00). Analyst Simos Simeonidis didn't like what he heard on the company's conference call regarding lead asset mirvetuximab soravtansine.
"We are downgrading IMGN to Sector Perform (from Outperform) on the news that lead asset mirvetuximab soravtansine produced a... More
Immunogen (IMGN) Misses Q3 EPS by 5c
April 29, 2016 8:33 AM EDTImmunogen (NASDAQ: IMGN) reported Q3 EPS of ($0.37), $0.05 worse than the analyst estimate of ($0.32). Revenue for the quarter came in at $19.7 million versus the consensus estimate of $23.02 million.
For earnings history and earnings-related data on Immunogen (IMGN) click here.
... More